<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370223</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19 Networking group</org_study_id>
    <nct_id>NCT04370223</nct_id>
  </id_info>
  <brief_title>Ozone Auto-hemotherapy for COVID-19 Pneumonia</brief_title>
  <acronym>COVID-OZONE</acronym>
  <official_title>A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Nuestra Senora del Rosario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, controlled, open-label clinical trial testing the use of
      ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia.

      Eligible patients will be randomly assigned to receive either ozone auto-hemotherapy plus
      standard treatment, or standard treatment alone.

      Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood
      with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur
      every 12h during 5 days. Standard treatment will be the one used in each hospital
      participating in the trial.

      All analyses will be done according to the intention-to-treat principle
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2020</start_date>
  <completion_date type="Anticipated">December 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 25, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients achieving improvement in clinical condition at day 14 after recruitment</measure>
    <time_frame>14 days</time_frame>
    <description>Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving improvement in clinical condition at day 28 after recruitment</measure>
    <time_frame>28 days</time_frame>
    <description>Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving improvement in clinical condition at day 7 after recruitment</measure>
    <time_frame>7 days</time_frame>
    <description>Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical improvement or hospital discharge</measure>
    <time_frame>28 days</time_frame>
    <description>Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ventilator-free days at 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator-free days from last extubation day until day 28 after recruitment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28 days</time_frame>
    <description>Days hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-fold decrease in ferritin</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days until a 2-fold decrease in ferritin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-fold decrease in C-protein reactive</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days until a 2-fold decrease in C-Protein Reactive (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-fold decrease in Dimer-D</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days until a 2-fold decrease in Dimer-D (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-fold decrease in Lactate Dehydrogenase</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days until a 2-fold decrease in Lactate Dehydrogenase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio</measure>
    <time_frame>14 days</time_frame>
    <description>Number of days until a 2-fold decrease in Neutrophils to Lymphocytes ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Ozone auto-hemotherapy plus standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment will be the one used in each hospital participating in the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ozone auto-hemotherapy</intervention_name>
    <description>ozone auto-hemotherapy</description>
    <arm_group_label>Ozone auto-hemotherapy plus standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COVID-19 confirmed by positive polymerase chain reaction (PCR) for Severe
             Acute Respiratory Syndrome (SARS-COV-2) in respiratory tract sample, plus pneumonia
             confirmed by imaging tests and arterial oxygen saturation (SpO2) &lt;94% with ambient air
             or a partial pressure of oxygen to fraction of inspired oxygen (pO2/FiO2) ratio &lt;300
             mmHg or SpO2/FiO2 ≤ 315.

          -  Acceptance to participate in the study and signing of the informed consent.

        Exclusion Criteria:

          -  Patients who have received treatment with any form of ozone therapy 6 months before
             admission to the hospital.

          -  Patients who have previously been treated and have experienced some type of adverse
             reaction to ozone therapy.

          -  Patients aware of having a deficiency of Glucose-6-phosphate dehydrogenase.

          -  Patients with clinically decompensated chronic comorbidities, independently of
             COVID-19.

          -  Patients suffering from any psychiatric disorder specified in axis I of the Diagnostic
             and Statistical Manual of Mental Disorders (DSM-V), other than major depression.

          -  Patients who are not able to clearly understand the objectives and methodology of the
             study.

          -  Pregnant or lactating patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Hernández, MD, PhD</last_name>
    <phone>+34 637930993</phone>
    <email>albimar23@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Vives, MD, PhD</last_name>
    <phone>+34 690277088</phone>
    <email>marcvives50@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Dr Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Nuestra Señora del Rosario</name>
      <address>
        <city>Ibiza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quirón Rey Juan Carlos I</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Noelia Zurera Plaza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Javier Ripolles, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias de Alcalá de Henares</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Angel Garcia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Althaia de Manresa</name>
      <address>
        <city>Manresa</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Antònia Flor, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Valencia Consuelo</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Baeza, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Eduardo Tamayo, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Claro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta</investigator_affiliation>
    <investigator_full_name>Marc Vives</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Ozone therapy</keyword>
  <keyword>Covid-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

